Zacks Research lowered its second-quarter 2026 earnings per share (EPS) estimates for Gilead Sciences (NASDAQ:GILD).
The firm now forecasts a Q2 EPS of ($6.99).
This replaces the previous estimate of $1.99.
Zacks also projected a third-quarter 2026 EPS of $1.84.
The firm adjusted its full-year 2026 forecast to ($1.05) EPS.
Gilead's latest quarterly report surpassed analyst expectations.
A consensus of 29 brokerage firms maintains a "Moderate Buy" rating.
Gilead recently affirmed its full-year 2026 guidance of -1.050 to -0.650 EPS.